Trade Agios Pharmaceuticals, Inc. - AGIO CFD

Trading Conditions

• Spread: 0.11
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 31.45
• Open: 31.45
• 1-Year Change: 40.4%
• Day's Range: 31.31 - 31.86

Agios Pharmaceuticals, Inc. Company profile

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Agios Pharmaceuticals Inc revenues was not reported. Net loss before extraordinary items increased 8% to $356.5M. Higher net loss reflects Research and development increase of 20% to $232.4M (expense), General and administrative increase of 15% to $92.5M (expense), Interest Income decrease of 87% to $836K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$4.77 to -$5.90.

Equity composition

Common Stock $.001 Par, Shares auth and O/s after the offering: 78.3 M auth., 29,380,399 issd. Insider Owns approx.38.04%.(After the IPO) IPO:TBA.